You are using an older browser version. Please use a supported version for the best MSN experience.

U.S. FDA approves Biogen Alzheimer's drug, shares soar

U.S. regulators on Monday approved Biogen's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease, despite controversy over whether the clinical evidence proves the drug works. Lisa Bernhard produced this report.
image beaconimage beaconimage beacon